Crestline Management LP Grows Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Crestline Management LP raised its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 97.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 160,347 shares of the company's stock after acquiring an additional 79,032 shares during the quarter. Crestline Management LP owned approximately 0.25% of Vera Therapeutics worth $6,781,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Barclays PLC lifted its stake in shares of Vera Therapeutics by 94.1% in the third quarter. Barclays PLC now owns 85,395 shares of the company's stock worth $3,774,000 after acquiring an additional 41,394 shares during the period. SG Americas Securities LLC lifted its position in shares of Vera Therapeutics by 116.7% in the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock worth $857,000 after purchasing an additional 10,916 shares during the period. KBC Group NV lifted its position in shares of Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after purchasing an additional 1,387 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Vera Therapeutics by 27.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,427 shares of the company's stock worth $568,000 after buying an additional 2,882 shares during the period. Finally, Jennison Associates LLC raised its stake in Vera Therapeutics by 82.0% during the fourth quarter. Jennison Associates LLC now owns 813,861 shares of the company's stock worth $34,418,000 after buying an additional 366,763 shares during the last quarter. Institutional investors own 99.21% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on VERA shares. Wedbush cut their target price on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research note on Wednesday. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They issued a "buy" rating and a $58.00 target price for the company. Cantor Fitzgerald dropped their price target on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research note on Wednesday. HC Wainwright started coverage on Vera Therapeutics in a report on Monday, May 5th. They issued a "buy" rating and a $75.00 price target on the stock. Finally, JPMorgan Chase & Co. decreased their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $63.33.

Vera Therapeutics Trading Down 1.2 %

Shares of VERA stock traded down $0.26 during mid-day trading on Friday, reaching $21.77. The stock had a trading volume of 1,262,456 shares, compared to its average volume of 778,875. The firm has a market capitalization of $1.39 billion, a PE ratio of -8.34 and a beta of 1.28. The stock's 50-day moving average price is $24.22 and its two-hundred day moving average price is $34.68. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter last year, the company earned ($0.56) earnings per share. Equities analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.